Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNEERING CORPORATION

(IMRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IMMUNEERING CORP : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

09/09/2021 | 06:32am EDT

Item 2.02. Results of Operations and Financial Condition.

On September 9, 2021, Immuneering Corporation (the "Company") announced its financial results for the quarter ended June 30, 2021 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report").

The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


The following exhibits relate to Item 2.02, which shall be deemed to be furnished, and not filed:




Exhibit
No.        Description
99.1         Press Release issued on September 9, 2021
104        Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses

Stocks mentioned in the article
ChangeLast1st jan.
IMMUNEERING CORPORATION 0.93% 27.14 Delayed Quote.0.00%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED -2.63% 8.695 Delayed Quote.-7.46%
All news about IMMUNEERING CORPORATION
10/11IMMUNEERING : Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC Internati..
AQ
10/11Immuneering Corporation Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EO..
CI
10/01IMMUNEERING : to Present Key Preclinical Data Across Several Poster Presentations at AACR-..
AQ
09/20IMMUNEERING : Announces Inclusion in the Russell 2000« Index
AQ
09/20IMMUNEERING CORPORATION(NASDAQGM : IMRX) added to S&P TMI Index
CI
09/09IMMUNEERING : Earnings Flash (IMRX) IMMUNEERING CORPORATION Reports Q2 Revenue $660,040
MT
09/09IMMUNEERING : Q2 Loss Widens, Revenue Grows
MT
09/09IMMUNEERING : Management's discussion and analysis of financial condition and results of o..
AQ
09/09IMMUNEERING CORP : Results of Operations and Financial Condition, Financial Statements and..
AQ
09/09Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates
GL
More news
Analyst Recommendations on IMMUNEERING CORPORATION
More recommendations
Financials (USD)
Sales 2021 2,79 M - -
Net income 2021 -35,4 M - -
Net cash 2021 128 M - -
P/E ratio 2021 -7,82x
Yield 2021 -
Capitalization 697 M 697 M -
EV / Sales 2021 204x
Capi. / Sales 2022 381x
Nbr of Employees 34
Free-Float 73,1%
Chart IMMUNEERING CORPORATION
Duration : Period :
Immuneering Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNEERING CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 26,89 $
Average target price 43,67 $
Spread / Average Target 62,4%
EPS Revisions
Managers and Directors
Benjamin J. Zeskind President, Chief Executive Officer & Director
Biren Amin Chief Financial Officer & Treasurer
Robert J. Carpenter Chairman
Scott Barrett Chief Medical Officer
Brett Hall Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
IMMUNEERING CORPORATION0.00%697
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.00%25 528